NCT07492927 Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
| NCT ID | NCT07492927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Clinically Significant Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,700 participants |
| Start Date | 2021-03-12 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,700 participants in total. It began in 2021-03-12 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Eligibility Criteria
Inclusion Criteria: 1. Blood prostate-specific antigen PSA\>4ng/dl; 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging. 3. The patient is willing to undergo prostate biopsy. Exclusion Criteria: 1. Previous diagnosis of prostate cancer through prostate biopsy; 2. History of other malignant tumors in the past two years; 3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Contact & Investigator
Weijun Qin, MD.
STUDY CHAIR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT07492927 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Clinically Significant Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07492927 currently recruiting?
Yes, NCT07492927 is actively recruiting participants. Contact the research team at 1531769428@qq.com for enrollment information.
Where is the NCT07492927 trial being conducted?
This trial is being conducted at Chicago, United States, Lanzhou, China, Yinchuan, China, Xining, China and 6 additional locations.
Who is sponsoring the NCT07492927 clinical trial?
NCT07492927 is sponsored by Xijing Hospital. The principal investigator is Weijun Qin, MD. at Xijing Hospital. The trial plans to enroll 1,700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.